What is Emboline?
Founded in 2011 and based in Santa Cruz, California, Emboline, Inc. is an emerging medical device company focused on addressing embolic risks in procedures such as TAVR (Transcatheter Aortic Valve Replacement). The company's flagship product, the Emboliner Embolic Protection Catheter, is designed to safeguard the cerebral system and capture non-cerebral debris. This novel technology, stemming from intellectual property developed by Amir Belson, aims to enhance patient safety in high-risk interventions. Emboline's development trajectory suggests a company moving towards commercialization and market penetration in the specialized field of cardiovascular intervention.
How much funding has Emboline raised?
Emboline has raised a total of $80M across 4 funding rounds:
Series B
$10M
Other Financing Round
$5M
Series C
$10M
Series D
$55M
Series B (2018): $10M with participation from ShangBay Capital and SV Tech Ventures
Other Financing Round (2020): $5M led by Undisclosed
Series C (2021): $10M, investors not publicly disclosed
Series D (2021): $55M featuring Global Assets Investment, Matrix Capital Management, ShangBay Capital, and SV Tech
Key Investors in Emboline
ShangBay Capital
ShangBay Capital is a venture capital firm specializing in medical devices, biotechnology, and healthcare, with a focus on seed and early-stage investments. The firm was established in 2015 and is headquartered in Palo Alto, California.
SV Tech Ventures
SV Tech Ventures is an investment entity that has shown interest in technology and potentially medical device companies, as indicated by its participation in Emboline's funding rounds.
Matrix Capital Management
Matrix Capital Management Company is an investment fund with a focus on technology and life sciences, headquartered in Waltham, Massachusetts.
What's next for Emboline?
The recent major strategic investment signals a pivotal growth phase for Emboline, likely enabling the company to scale its operations, expand its clinical trials, and prepare for broader market adoption. This infusion of capital, following previous rounds including Series C and Series D financing, positions Emboline to further refine its technology and navigate the complex regulatory landscape. The company's focus on a critical unmet need in interventional cardiology suggests a strong potential for future expansion and strategic partnerships within the healthcare sector.
See full Emboline company page
